[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![$akesf Graphic](https://lunarcrush.com/gi/w:26/t:$akesf.png) $akesf

$AKESF sees a surge in engagements due to positive clinical trial data in China. Market volatility remains a concern despite the positive news.

### About $akesf
A cryptocurrency project.  

### Engagements: XXXXX [#](/topic/$akesf/interactions)
---
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$akesf/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$akesf/time-series/interactions.tsv)  
**Current Value**: XXXXX  
**Daily Average**: XXX  
**1 Week**: XXXXX +21,790%  
**1 Month**: XXXXX +74%  
**1-Year High**: XXXXXX on 2025-04-28  
**1-Year Low**: X on 2025-06-02  

| Social Network | X     |
| -------------- | -     |
| Engagements    | XXXXX |
  

  
  
### Mentions: X [#](/topic/$akesf/posts_active)
---
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$akesf/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$akesf/time-series/posts_active.tsv)  
**Current Value**: X  
**Daily Average**: X  
**1 Month**: X -XX%  
**1-Year High**: XX on 2025-04-30  
**1-Year Low**: X on 2025-05-10  

| Social Network | X |
| -------------- | - |
| Mentions       | X |
  

  
  
### Creators: X [#](/topic/$akesf/contributors_active)
---
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$akesf/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$akesf/time-series/contributors_active.tsv)  
X unique social accounts have posts mentioning $akesf in the last XX hours which is up XX% from X in the previous XX hours
**Daily Average**: X  
**1 Month**: X no change  
**1-Year High**: X on 2025-04-30  
**1-Year Low**: X on 2025-05-04  

The most influential creators that mention $akesf in the last XX hours

| Creator                                          | Rank | Followers | Posts | Engagements |
| -------                                          | ---- | --------- | ----- | ----------- |
| [@MarcJacksonLA](/creator/twitter/MarcJacksonLA) | X    | XXXXX     | X     | XXXXX       |

[View More](/list/creators/$akesf/100)

**Top assets mentioned**
In the posts about $akesf in the last XX hours

[Summit Therapeutics Inc. Common Stock (SMMT)](/topic/$smmt)
[One Cash (ONC)](/topic/$onc)
[Merck & Co., Inc. (MRK)](/topic/$mrk)

**Top topics mentioned**
In the posts about $akesf in the last XX hours

[$smmt](/topic/$smmt), [china](/topic/china), [$9926hk](/topic/$9926hk), [$14bn](/topic/$14bn), [$psnl](/topic/$psnl), [$onc](/topic/$onc), [$mrk](/topic/$mrk), [coins stablecoin](/topic/coins-stablecoin), [$3m](/topic/$3m)

### Top Social Posts [#](/topic/$akesf/posts)
---
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"Great Data out on $SMMT Huge move coming Monday This can see a $XXXXX move"  
[X Link](https://x.com/trentkelp/status/1979969463895146528) [@trentkelp](/creator/x/trentkelp) 2025-10-19T17:54Z 7570 followers, 1463 engagements


"$AKESF $SMMT $ONC $MRK ESMO 2025: Akeso Summit's ivonescimab beats PD-1 in first chemo combo win in first-line NSCLC - Ivonescimab and chemo reduced the risk of progression or death by XX% compared with BeOnes Tevimbra and chemo in first-line squamous NSCLC"  
[X Link](https://x.com/MarcJacksonLA/status/1979943276066279807) [@MarcJacksonLA](/creator/x/MarcJacksonLA) 2025-10-19T16:10Z 7578 followers, XXX engagements


"$SMMT $AKESF ESMO 2025: Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by XX% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Clinically Meaningful Benefit over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase X Clinical Trial in 1L NSCLC: Median PFS of XXXXX Months vs. XXXX Months Respectively for Patients Receiving Ivonescimab Plus Chemotherapy vs."  
[X Link](https://x.com/MarcJacksonLA/status/1979930068978991176) [@MarcJacksonLA](/creator/x/MarcJacksonLA) 2025-10-19T15:18Z 7578 followers, 1897 engagements


"$SMMT $AKESF HARMONi-6 Still Chinese data still impressive now in first line NSCLC against Tislelizumab. Still no OS "  
[X Link](https://x.com/PersimmonTI/status/1979927758089212030) [@PersimmonTI](/creator/x/PersimmonTI) 2025-10-19T15:08Z 10.3K followers, 4964 engagements